^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    pan-KRAS inhibitor

    Related drugs:
    6d
    BGB-53038-101: A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification (clinicaltrials.gov)
    P1, N=177, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Erbitux (cetuximab) • Tevimbra (tislelizumab-jsgr)
    1m
    A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    3ms
    A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    3ms
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • BI 1701963
    4ms
    A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplification (clinicaltrials.gov)
    P1, N=177, Not yet recruiting, BeiGene
    New P1 trial • Metastases
    6ms
    BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. (PubMed, Cell Commun Signal)
    This study uncovered a new application of BI-2865 as a MDR modulator, which might be used to effectively, safely and specifically improve chemotherapeutic efficacy in the clinical P-gp mediated MDR refractory cancers.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    paclitaxel • doxorubicin hydrochloride • vincristine
    8ms
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Mar 2024 --> Oct 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • BI 1701963
    10ms
    A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Aug 2023
    Enrollment open • Trial initiation date • Metastases
    10ms
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Mar 2024 --> Oct 2024
    Trial completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • BI 1701963
    11ms
    A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=110, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    1year
    Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Shanghai YingLi Pharmaceutical Co. Ltd.
    New P1 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • HRAS mutation
    |
    YL-17231
    1year
    A Study of YL-17231 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=80, Recruiting, Shanghai YingLi Pharmaceutical Co. Ltd.
    New P1 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • KRAS wild-type • RAS wild-type
    |
    YL-17231
    over1year
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • BI 1701963
    almost2years
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Feb 2023 --> Sep 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • BI 1701963
    almost2years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=8, Terminated, Boehringer Ingelheim | Completed --> Terminated; Sponsor decision
    Preclinical • Trial termination • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    almost2years
    A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov)
    P1, N=8, Completed, Boehringer Ingelheim | Terminated --> Completed
    Trial completion
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12 • KRAS G13 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 4 mutation
    |
    LNP3794 • BI 1701963
    almost2years
    CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov)
    P1b/2, N=1143, Recruiting, Amgen | Trial completion date: Oct 2026 --> Jun 2027 | Trial primary completion date: Aug 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • zeluvalimab (AMG 404)
    2years
    Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) (clinicaltrials.gov)
    P1, N=7, Completed, Mirati Therapeutics Inc. | Active, not recruiting --> Completed | N=100 --> 7 | Trial completion date: Feb 2024 --> Nov 2022 | Trial primary completion date: Nov 2023 --> Nov 2022
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib) • BI 1701963